The Experts below are selected from a list of 26955 Experts worldwide ranked by ideXlab platform

Yuwu Zhao - One of the best experts on this subject based on the ideXlab platform.

  • Serum Neuron Specific Enolase level as a predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis.
    Journal of the neurological sciences, 2015
    Co-Authors: Shasha Cui, Feng Wang, Bin Zhang, Yuwu Zhao
    Abstract:

    Serum Neuron Specific Enolase (NSE) concentrations are significantly correlated with stroke severity and clinical outcome in ischemic stroke patients. We aimed to determine whether the serum levels of Neuron Specific Enolase in acute ischemic stroke (AIS) patients after intravenous thrombolysis are associated with stroke severity, and indicative of favorable outcome. We prospectively analyzed the serum Neuron Specific Enolase levels with for 67 subjects with AIS patients treated with intravenous recombinant tissue type plasminogen activator (rtPA) within 4.5h from symptom onset. Neurologic deficit was assessed by the National Institutes of Health Stroke Scale. Clinical outcome was assessed after 90days according to the modified Rankin Scale. Neuron Specific Enolase levels correlated with National Institutes of Health Stroke Scale score 24h after rtPA bolus (R=0.342, p=0.005). Regarding the 67 included patients, 32 (47.8%) reached favorable outcome. They had a lower NIHSS score on admission (p=0.000) and at 24h after rtPA bolus (p=0.000), and had lower levels of Neuron Specific Enolase (p=0.006). But only NIHSS score at 24h after rtPA bolus rather than Neuron Specific Enolase level was an independent predictor for favorable outcome. We found that after treatment with intravenous rtPA therapy, lower serum Neuron Specific Enolase levels were associated with favorable outcome, which may be confounded by the link to NIHSS score. Copyright © 2015 Elsevier B.V. All rights reserved.

  • Serum Neuron Specific Enolase level as a predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis
    Journal of the Neurological Sciences, 2015
    Co-Authors: Shasha Cui, Feng Wang, Bin Zhang, Yuwu Zhao
    Abstract:

    Abstract Objective Serum Neuron Specific Enolase (NSE) concentrations are significantly correlated with stroke severity and clinical outcome in ischemic stroke patients. We aimed to determine whether the serum levels of Neuron Specific Enolase in acute ischemic stroke (AIS) patients after intravenous thrombolysis are associated with stroke severity, and indicative of favorable outcome. Methods We prospectively analyzed the serum Neuron Specific Enolase levels with for 67 subjects with AIS patients treated with intravenous recombinant tissue type plasminogen activator (rtPA) within 4.5 h from symptom onset. Neurologic deficit was assessed by the National Institutes of Health Stroke Scale. Clinical outcome was assessed after 90 days according to the modified Rankin Scale. Results Neuron Specific Enolase levels correlated with National Institutes of Health Stroke Scale score 24 h after rtPA bolus (R = 0.342, p = 0.005). Regarding the 67 included patients, 32 (47.8%) reached favorable outcome. They had a lower NIHSS score on admission (p = 0.000) and at 24 h after rtPA bolus (p = 0.000), and had lower levels of Neuron Specific Enolase (p = 0.006). But only NIHSS score at 24 h after rtPA bolus rather than Neuron Specific Enolase level was an independent predictor for favorable outcome. Conclusion We found that after treatment with intravenous rtPA therapy, lower serum Neuron Specific Enolase levels were associated with favorable outcome, which may be confounded by the link to NIHSS score.

Anders Isaksson - One of the best experts on this subject based on the ideXlab platform.

Shasha Cui - One of the best experts on this subject based on the ideXlab platform.

  • Serum Neuron Specific Enolase level as a predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis.
    Journal of the neurological sciences, 2015
    Co-Authors: Shasha Cui, Feng Wang, Bin Zhang, Yuwu Zhao
    Abstract:

    Serum Neuron Specific Enolase (NSE) concentrations are significantly correlated with stroke severity and clinical outcome in ischemic stroke patients. We aimed to determine whether the serum levels of Neuron Specific Enolase in acute ischemic stroke (AIS) patients after intravenous thrombolysis are associated with stroke severity, and indicative of favorable outcome. We prospectively analyzed the serum Neuron Specific Enolase levels with for 67 subjects with AIS patients treated with intravenous recombinant tissue type plasminogen activator (rtPA) within 4.5h from symptom onset. Neurologic deficit was assessed by the National Institutes of Health Stroke Scale. Clinical outcome was assessed after 90days according to the modified Rankin Scale. Neuron Specific Enolase levels correlated with National Institutes of Health Stroke Scale score 24h after rtPA bolus (R=0.342, p=0.005). Regarding the 67 included patients, 32 (47.8%) reached favorable outcome. They had a lower NIHSS score on admission (p=0.000) and at 24h after rtPA bolus (p=0.000), and had lower levels of Neuron Specific Enolase (p=0.006). But only NIHSS score at 24h after rtPA bolus rather than Neuron Specific Enolase level was an independent predictor for favorable outcome. We found that after treatment with intravenous rtPA therapy, lower serum Neuron Specific Enolase levels were associated with favorable outcome, which may be confounded by the link to NIHSS score. Copyright © 2015 Elsevier B.V. All rights reserved.

  • Serum Neuron Specific Enolase level as a predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis
    Journal of the Neurological Sciences, 2015
    Co-Authors: Shasha Cui, Feng Wang, Bin Zhang, Yuwu Zhao
    Abstract:

    Abstract Objective Serum Neuron Specific Enolase (NSE) concentrations are significantly correlated with stroke severity and clinical outcome in ischemic stroke patients. We aimed to determine whether the serum levels of Neuron Specific Enolase in acute ischemic stroke (AIS) patients after intravenous thrombolysis are associated with stroke severity, and indicative of favorable outcome. Methods We prospectively analyzed the serum Neuron Specific Enolase levels with for 67 subjects with AIS patients treated with intravenous recombinant tissue type plasminogen activator (rtPA) within 4.5 h from symptom onset. Neurologic deficit was assessed by the National Institutes of Health Stroke Scale. Clinical outcome was assessed after 90 days according to the modified Rankin Scale. Results Neuron Specific Enolase levels correlated with National Institutes of Health Stroke Scale score 24 h after rtPA bolus (R = 0.342, p = 0.005). Regarding the 67 included patients, 32 (47.8%) reached favorable outcome. They had a lower NIHSS score on admission (p = 0.000) and at 24 h after rtPA bolus (p = 0.000), and had lower levels of Neuron Specific Enolase (p = 0.006). But only NIHSS score at 24 h after rtPA bolus rather than Neuron Specific Enolase level was an independent predictor for favorable outcome. Conclusion We found that after treatment with intravenous rtPA therapy, lower serum Neuron Specific Enolase levels were associated with favorable outcome, which may be confounded by the link to NIHSS score.

Adnan Ceviz - One of the best experts on this subject based on the ideXlab platform.

  • serum Neuron Specific Enolase as a predictor of short term outcome and its correlation with glasgow coma scale in traumatic brain injury
    Neurosurgical Review, 2008
    Co-Authors: Aslan Guzel, Mehmet Tatli, Ufuk Aluclu, Umit Ozkan, Yucel Duzenli, Omer Satici, Ebru Guzel, Serdar Kemaloglu, Uygur Er, Adnan Ceviz
    Abstract:

    Elevated serum Neuron-Specific Enolase levels are correlated with brain cell damage. Low scores according to Glasgow Coma Scale are also considered as serious poor prognostic factor. The aims of the study were to investigate whether there is a correlation between the two measurements in patients with traumatic brain injury and whether serum Neuron-Specific Enolase levels have potential as a screening test to predict outcome. A total of 169 consecutive patients with traumatic brain injury admitted to our clinic between 2002 and 2005 are included in this study. Those patients, who had any major health problem before trauma, were excluded from the study. However, patients with isolated head injury were included in the study. Serial serum Neuron-Specific Enolase concentrations taken at the first 2, 24, and 48 h after traumatic brain injury were analyzed. A computed tomography was performed on each patient on admission. Their Glasgow Coma Scale scores were recorded serially. The relationship between Glasgow Coma Scale scores and the serum Neuron-Specific Enolase levels were assessed by statistical methods. There was a significant negative correlation between the serum Neuron-Specific Enolase levels and Glasgow Coma Scale scores. The levels of Neuron-Specific Enolase were significantly higher in the patients who died in 30 days after trauma and whose scores were lower than or equal to 8 points in Glasgow Coma Scale. Although there are several serious limitations of the use of Neuron-Specific Enolase as a biomarker in traumatic brain injury (i.e., hypoperfusion, extracranial trauma, bleeding, liver, or kidney damage also increase the level of Neuron-Specific Enolase), its concentrations may be useful as a practical and helpful screening test to identify neurotrauma patients who are at increased risk and may provide supplementary estimation with radiological and clinical findings.

Malin Rundgren - One of the best experts on this subject based on the ideXlab platform.